, often at their second (P2) and last positions, and are generally eight to ten residues long [3] [4] [5] [6] . These anchor residues fit into specificity pockets in the binding groove that are found in class I proteins from both human [7-91 and mouse [lO,l 11 . With their second and last residues fitted into pockets, peptides tend to arch away from the MHC molecule from about residues P4 to P7; these same residues have the greatest sequence variation (reviewed in [12] ). Presumably, this central region is the most important element in the interaction with the TCR. Peptidic ligands to single subtypes of MHC molecules have been designed [13, 14] , but suffer from poor bio-availability in human sera [15] . We sought to replace the variable domains of MHC-binding peptides with a non-peptidic moiety, while retaining the ability of the terminal residues to bind to the ends of the peptide-binding groove in specific MHC class I proteins.
Results and discussion
From the refined X-ray structure of a peptide presented by the MHC class I molecule HLA-Aw68
[16], two bonds, along the peptide backbone and flanking the variable region, were identified as candidate parameters for ligand design (Fig. l) .The two bonds, represented as two vectors (Fig. 2a) , were used in a computational search [17, 18] [20]), we turned our attention to the 3,%disubstituted phenanthracene ring system, in part due to its rigid conformation. An aza analog (phenanthridine) of this molecule was selected since a starting material for ligands incorporating this element, 3,8-diamino-6-phenyl-phenanthridine, is commercially available. A rapid and modular synthesis of the phenanthridine linker was accomplished by using an isocyanate of the penultimate residue [21] , which reacted with phenanthridine site-specifically to yield a urea. Based upon NMR spectroscopic analysis, the reaction appears to occur at the more nucleophilic amino group at the 3-position, although we note that a highly similar spacer element would result from isocyanate coupling at the &position.
Solid-phase methods were used to complete the syntheses of the ligands (Fig. 3) show that the phenanthridine-based ligand bound in an orientation that is essentially identical to the parent peptide, with the central residues of the peptide replaced by the flat phenanthridine ring (Fig. 4) to the parent peptide complex (T, = 68 "C) (Fig. 5a ).This T, of 56 "C is within the normal range of class I MHC-peptide complexes.
The fluorescence of the phenanthridine moiety was exploited to measure half lives for binding of phenanthridine-based ligands to MHC molecules. When these ligands dissociate from the protein complex, the fluorescence intensity of the phenanthridine chromophore increases (Fig. 5b) The strategy of replacing variable regions was also successful in all other subtypes of MHC class I molecules examined (Table 1 ). The anchor residues of the ligand must match the requirements of the targeted MHC class I protein; mismatched anchor residues and MHC class I molecules did not result in folded complexes. Six phenanthridine-based ligands derived from five parent peptides were synthesized; as anticipated from the specificities of the parent peptides, two were specific for HLA-A2.1, three for HLA-Aw68 and one for HLA-B27. For both HLA-A2.1 and HLA-Aw68, ligands based on decamer and nonamer peptides were synthesized; one ligand based on a nonamer was synthesized for HLA-B27.
In each case, subtype-specific binding of ligand to MHC molecule was observed. The phenanthridine spacer was used to replace three amino acids in three different nonameric peptides, four amino acids in two decameric peptides, and five amino acids in a decameric peptide (Table 1 ). The length of the planar spacer is -11.5 A. The X-ray crystal structures of all of the parent peptides complexed with their respective MHC 'molecules have been determined previously ([23,29] and E.J.C., unpublished data). The distance that the spacer replaces, measured in the complexes of the parent peptides with MHC molecules ([23,29,3!] and E.J.C., unpublished data), was between 8.1 A and 12.9 A. This variation indicates that there is some accommodation in the position of the amino acids at the joints with the spacer, suggesting that the phenanthridine spacer element can be made to bind in a Fig.  2 using standard laboratory procedures. All compounds were characterized by infrared spectroscopy, 'H NMR, and fast atom bombardment (FAB) 'mass spectroscopy or high resolution mass spectroscopy (HRMS). The first amino acid coupled to compounds 4, 5, 6a,b,c,d ' and all arginines were double coupled. Reverse phase HPLC (ligand dependent solvent gradient of 100:0 to 70:30 or 50:50 0.1 % trifluoroacetic acid in H20:acetonitrile) was used to purify the ligands.
Synthesis of 621
To a 0.1 M THF solution of a hydrochloride salt 3a (1.158 g, 3.5 mmol, 1 equiv), triphosgene (0.343 g, 1.16 mmol, 0.33 equiv) inTHF (5 ml) was added. i-PrzNEt (3.1 ml, 17.5 mmol, 5 equiv) was added slowly, and the solution was stirred for one hour at room temperature. Strong infrared absorbance at 2253 cm-l verified the presence of an isocyanate. This solution was cooled to 0 "C and added slowly via syringe to an ice-cold THF (20 ml) solution of 3,8-diamino-6-phenyl-phenanthridine (1.0 g, 3.5 mmol, 1 equiv), which was allowed to warm gradually to room temperature. heavy chain and &rn were purified from an Escherichia coli expression system, as described previously [22] . After being individually diluted ten-fold in 8 M urea, heavy chain (final concentration of 1 PM) and &rn (final concentration of 2 PM) were added to 45 ml of 100 mM Tris (pH = 8), 400 mM L-arginine, 0.5 mM Na2EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, containing 50 PM phenanthridine-based ligand.After incubating for 36 h at 10 "C, the solution was concentrated with a Centriprep-10 followed by a Centricon-10, to a volume of 45 p.l.The concentrated protein was purified using gel filtration HPLC with an eluent of 20 mM Tris (pH = 7.5) containing 150 mM NaCl and had a retention time of 18 minutes (44 kD) in a Phenomenex
Biosep SEC-S3000 column. The 1.5 ml fraction containing the complex was concentrated to 45 p,l using a Centricon-10.
Thermal stability measurements Circular dichroism experiments were conducted in 10 mM MOPS (pH = 7.5), in a 1 mm cell. Concentrations (from 3 to 10 PM) of the complexes were determined spectrophotometrically (at 280 nm, E = 94 240 cm-' M-').The Aviv 62DS spectropolarimeter was equipped with a thermoelectric temperature controller.
Fluorescence kinetics Folded MHC class I-phenanthridine ligand complex (50 nM to 750 nM) was incubated at 37 "C and cooled to 10 "C before being excited at 310 nm and monitored for emission at 452 nm. Cuvettes remained inside the Hitachi F-2000 fluorimeter during the course of each experiment. The buffer contained 20 mM TRIS, 0.02 % NaN3, at pH = 7.5.
